Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomized, placebo-controlled clinical trial

International Urology and Nephrology

Volumn 45, Issue 1, 2013, Pages 39-43

  Regadas, Rommel Prata ^a   Reges, Ricardo ^a   Cerqueira, Joao Batista Gadelha ^a   Sucupira, Daniel Gabrielle ^a   Josino, Iatagan Rocha ^a   Nogueira, Emmanuel Almeida ^a   Jamacaru, Francisco Vagnaldo F ^a   De Moraes, Manoel Odorico ^a   Silva, Lucio Flavio Gonzaga ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Tadalafil; Tamsulosin; Urodynamic

Indexed keywords

PLACEBO; TADALAFIL; TAMSULOSIN;

ADULT; ARTICLE; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DETRUSOR MUSCLE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPOTENSION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION; MONOTHERAPY; MYALGIA; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINE FLOW RATE; URODYNAMICS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; CARBOLINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; SULFONAMIDES; URINARY BLADDER, OVERACTIVE; URINATION; URODYNAMICS;

EID: 84873410978     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0317-7     Document Type: Article

References (18)

1. Filippi S, Morelli A, Sandner P et al (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148(3):1019-1029
2. Shapiro E, Lepor H (1995) Pathophysiology of clinical benign prostatic hyperplasia. Urol ClinNAm22(2):285-290
3. Andersson KE, de Groat WC, McVary KT et al (2011) Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 30(3):292-301
4. Boyle P, Robertson C, Mazzetta C et al (2003) The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 92(7):719-725
5. Sairam K, Kulinskaya E, McNicholas TA et al (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90(9):836-839
6. McVary KT, Monnig W, Camps JL Jr. et al (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177(3):1071-1077
7. Roehrborn CG, McVary KT, Elion-Mboussa A et al (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180(4):1228-1234
8. Stief CG, Porst H, Neuser D et al (2008) A randomised, placebo-controlled study to assess the efficacy of twicedaily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53(6):1236-1244
9. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170(2 Pt 1):530-547
10. Oger S, Behr-Roussel D, Gorny D et al (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 6(3):836-847
11. Schafer W, Abrams P, Liao L et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressureflow studies. Neurourol Urodyn 21(3):261-274
12. Bechara A, Romano S, Casabe A et al (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5(9):2170-2178
13. Oger S, Behr-Roussel D, Gorny D et al (2010) Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 57(4):699-707
14. Griffiths DJ (1973) The mechanics of the urethra and of micturition. Br J Urol 45(5):497-507
15. Dmochowski R, Roehrborn C, Klise S et al (2010) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 183(3):1092-1097
16. Kedia GT, Uckert S, Jonas U et al (2008) The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26(6): 603-609
17. Monica FZ, Reges R, Cohen D et al (2011) Long-term administration of BAY 41-2272 prevents bladder dysfunction in nitric oxide-deficient rats. Neurourol Urodyn 30(3):456-460
18. Uckert S, Sormes M, Kedia G et al (2008) Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71(3):526-530